ArticleThe Pan African medical journal2026
From fang to lung: pulmonary embolism following snake envenomation (a case report).
Article in The Pan African medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism is an uncommon complication of snake envenomation. While venom-induced consumption coagulopathy typically produces hemorrhagic manifestations, thrombotic complications can paradoxically develop, requiring careful timing of anticoagulation given competing hemorrhagic risks. We report a 65-year-old woman without thromboembolic risk factors who presented 3 days after a snake bite with progressive lower limb swelling and dyspnea. Physical examination revealed unilateral edema with visible fang marks. Despite normalized coagulation parameters, markedly elevated D-dimers prompted computed tomography pulmonary angiography, which demonstrated bilateral segmental pulmonary embolism without detectable lower extremity deep vein thrombosis. The patient was treated with therapeutic anticoagulation using low-molecular-weight heparin followed by rivaroxaban for 6 months, achieving complete resolution without hemorrhagic complications. Snake venom disrupts hemostasis through a biphasic response: initial consumption coagulopathy depleting factors and platelets, potentially followed by a compensatory prothrombotic phase with hyperfibrinogenemia and thrombocytosis. Additionally, specific venom proteases directly cleave fibrinopeptides A and B from fibrinogen while activating factor XIII, creating stable cross-linked fibrin deposits resistant to fibrinolysis. The absence of deep vein thrombosis suggests thrombogenesis occurs through in situ pulmonary mechanisms or undetectable microemboli. The favorable outcome supports safe initiation of therapeutic anticoagulation once acute coagulopathy resolves. Pulmonary embolism, though rare, can complicate snake envenomation even when coagulation parameters are normalized and deep vein thrombosis is absent. After coagulopathy resolves, anticoagulation is safe. Monitoring for thromboembolic events beyond the acute hemorrhagic phase remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.